CGM alarms often not set to alert children with diabetes to harmful blood glucose fluctuations

Children and teenagers who use continuous glucose monitors (CGM) to manage diabetes often fail to use the appropriate alarm settings to alert to dangerously low or harmful high blood sugar levels, according to a study being presented Thursday at ENDO 2023, the Endocrine Society’s annual meeting in Chicago, Ill. This variability makes the monitors less useful in tracking glucose levels.

ENDO 2023 press conferences to highlight emerging technology and diabetes research

Researchers will delve into the latest research in diabetes, obesity, reproductive health and other aspects of endocrinology during the Endocrine Society’s ENDO 2023 news conferences June 15-18.

Technology use by adults with type 1 diabetes lower among African Americans, Hispanics

Continuous glucose monitor (CGM) and continuous subcutaneous insulin infusion (CSII) devices are known to improve outcomes in patients with type 1 diabetes (T1D), yet African American and Hispanic patients face barriers to the use of these devices, according to results of a small single-center retrospective study. The results of the ENDO 2020 abstract will be published in the Journal of the Endocrine Society.

Medtronic MiniMed 670G insulin pump allows “excellent” blood glucose control

Patients with type 1 diabetes who use Medtronic’s MiniMedTM 670G insulin pump system are able to maintain blood glucose levels in the targeted range over 71% of the time, according to a study that analyzed some 6 million days of real-world data. Results of the industry-supported study were accepted for presentation at ENDO 2020, the Endocrine Society’s annual meeting, and will be published in a special supplemental issue of the Journal of the Endocrine Society.